Maximus Review: The Best Safety Disclosure We've Seen — Attached to Headline Prices That Need a Six-Month Commitment

What Is Maximus?

Maximus is operated by Maximus Health, Inc., a Santa Monica company that the BBB records as having started trading on 16 February 2021 — five years, not the decade its positioning implies. It was founded by Dr. Cameron Sepah, and it is worth being precise about what that means: Sepah holds a PhD in clinical psychology from UCLA and a BA from Harvard, is a Professor of Psychiatry at UCSF, and was founding Medical Director of Omada Health. He is a doctor, but a psychologist rather than a physician. The prescribing is done by board-certified physicians the company employs, which is the normal and correct arrangement — just not the same thing as a physician-founded clinic.

The catalogue is the widest in men's telehealth. Testosterone runs across four protocols: injectable, cream, oral tablets and enclomiphene. Weight loss covers compounded semaglutide and tirzepatide plus six brand-name products. There is a blood-flow protocol built on PDE5 inhibitors, a hair-growth line spanning oral and topical, sermorelin injections for growth hormone, an oxytocin calming cream, prescription multivitamins, and lab panels of up to 146 markers.

The company's real distinction is disclosure. On its testosterone cream page it publishes transference risk, fertility suppression, polycythaemia, PSA elevation, sleep apnoea exacerbation and cardiovascular risk. On the blood-flow page it warns about nitrates, alpha-blockers and vardenafil's QT effect. On compounded products it prints, in capitals, that compounded medications are not FDA-approved for safety, efficacy or quality. It also volunteers that it uses base-form rather than salt-form semaglutide and explains why salt forms are a problem — a question almost no competitor will answer.

The gap between that candour and the company's commercial presentation is what this review is really about. Every protocol advertises a low monthly figure that requires prepaying six or twelve months, and the BBB complaint file describes a consistent pattern of customers being charged before treatment reached them.

Every Protocol and What It Actually Costs

Read the left column and the right column together, because the difference between them is the whole story. Injectable testosterone is advertised as 'starting at $99.99/mo' — that is the six-month plan rate. Buy a single month and it is $199.99, exactly double. Enclomiphene's $99.99 requires a twelve-month plan. Hair products quote monthly figures but are sold as 90-day supplies. The prices above were taken from maximustribe.com on 7 August 2026; Maximus notes they vary by dosage and 'may vary slightly by state.' Klarna instalments are offered on most protocols, which spreads a prepaid plan but does not shorten it.

Compounded, Off-Label and Unapproved — What the FDA Has Actually Said

Most of what Maximus sells is compounded, and it is unusually straight about that. Its pages carry the disclosure that compounded medications 'are not approved or evaluated for safety, efficacy, or quality by the FDA', and on the GLP-1 side it states in capitals that compounded medications are not FDA-approved for safety, efficacy or quality. It does not bury this.

It goes further than any provider we have reviewed on compounding chemistry. Asked whether it uses base form or salt form, Maximus answers plainly: base form only, and warns that some pharmacies use salt forms such as 'Semaglutide Sodium' or 'Semaglutide Acetate', which 'are different chemicals, are not equivalent, and have not been tested for safety or effectiveness'. That is the right answer to a question most patients do not know to ask.

Enclomiphene deserves a paragraph of its own, because it is the basis of the 'fertility-friendly' protocols Maximus promotes hardest and the regulatory position is weaker than the marketing suggests. There is no FDA-approved enclomiphene product in the United States. In 2022 the substance was nominated for the FDA's 503A Bulks List — the list of ingredients compounding pharmacies will be permitted to use once the rule is final. At its meeting on 8 June 2022 the FDA's Pharmacy Compounding Advisory Committee voted on whether enclomiphene citrate should go on that list. We read the official FDA transcript: the vote was four in favour and eight against, with no abstentions, and one member stated the reason as 'lack of convincing efficacy evidence for the agreeable, appropriate clinical endpoints.'

That vote is advisory, not binding, and the 503A rule has not been finalised, so compounding pharmacies have continued to supply enclomiphene under FDA's interim policy. Maximus is not doing anything unlawful. But if you are choosing enclomiphene over conventional TRT specifically to protect fertility, you should know you are choosing a drug that has never been FDA-approved and that FDA's own advisory committee recommended two-to-one against permitting for compounding. Ask your prescriber directly about it.

Two hair medications carry the same caveat in milder form. Maximus correctly labels oral finasteride as 'FDA approved' for hair loss. It does not apply that label to dutasteride, which is right — dutasteride is approved in the US for benign prostatic hyperplasia, not hair loss, so prescribing it for hair is off-label. Oral minoxidil is likewise off-label; only the topical form is approved for hair loss. Off-label prescribing is legal, common and often evidence-based, but it is not the same as approved.

Sermorelin is compounded and not an FDA-approved product. Maximus states no lab testing is required to qualify for it, which is convenient and worth thinking about — you are being prescribed a growth-hormone-releasing peptide without a baseline IGF-1. To the company's credit, its own FAQ addresses the cancer question honestly, says it will not prescribe to anyone with active cancer, and tells survivors to decide with their oncologist.

The Consultation Process

Eligibility

• •Adults only, and the testosterone and blood-flow protocols state plainly that they are 'not for use by women or anyone under 18'. The weight-loss protocol is open to both men and women.
• •State availability varies by protocol rather than across the platform. Sermorelin is available in every state except Alabama; the weight-loss protocol excludes Alabama, Mississippi and Louisiana; Maximus advises checking each product page for your state. Separately, this offer is not available to residents of Alaska, Washington state or Washington DC.
• •Testosterone therapy suppresses natural production and reduces sperm count — Maximus publishes this fertility warning directly. If preserving fertility matters, that is the trade-off the enclomiphene protocol is designed to address, subject to the regulatory caveat above.
• •Testosterone cream carries a transference risk to partners and children. Maximus instructs washing hands after application and covering the site with clothing, with the site washable after two hours. Take this seriously if there are children in the house.
• •Other testosterone risks Maximus publishes: polycythaemia and raised haematocrit (requiring CBC monitoring), elevated PSA, sleep apnoea exacerbation, cardiovascular events in high-risk individuals, acne, fluid retention, mood changes and DHT-driven hair loss in genetically predisposed men.
• •PDE5 inhibitors must never be combined with nitrates in any form — the combination can cause severe, potentially fatal hypotension. Use caution with alpha-blockers. They are contraindicated where sexual activity is inadvisable on cardiovascular grounds. Vardenafil prolongs the QT interval and should not be used with Class IA or Class III antiarrhythmics.
• •Seek immediate care for an erection lasting more than four hours, sudden vision loss, or sudden hearing loss or ringing in the ears.
• •Finasteride and dutasteride are 5-alpha-reductase inhibitors: they must not be handled by women who are or may become pregnant, can cause sexual side effects that some men report as persistent, and suppress PSA — tell any clinician measuring your PSA that you take one.
• •GLP-1 medicines are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and must not be used in pregnancy.
• •Maximus states it will not prescribe sermorelin to anyone with active cancer, and advises cancer survivors to decide alongside their oncologist.

Clinicians, Labs & Pharmacy

Shipping & Support Services

Free priority shipping on all protocols, in discreet packaging. Hair products ship as 90-day supplies despite monthly pricing.

• •Four distinct testosterone protocols — injectable, cream, oral and enclomiphene
• •Published whitepapers with named outcome figures rather than vague claims
• •Base-form-only compounding disclosed for semaglutide and tirzepatide
• •The most complete side-effect disclosure in men's telehealth, including transference and QT risk
• •Free tadalafil bundled into some testosterone protocols
• •Lab panels up to 146 markers available
• •Klarna instalments on most protocols
• •Free priority shipping throughout
• •Answers BBB complaints and issues four-figure refunds when at fault

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Maximus May Be Best For

• •Men who want testosterone and something else — weight loss, hair, ED — managed on one platform instead of three subscriptions
• •Anyone who wants a provider that will actually answer the base-form compounding question
• •Men who want fertility preserved and will discuss the enclomiphene regulatory position with a prescriber first
• •Buyers confident enough to commit six or twelve months up front, which is where the value genuinely is
• •People who read side-effect disclosures and want a company that publishes them properly

Limitations

• •The pricing architecture is the core problem and it is deliberate rather than sloppy. 'Starting at $99.99/mo' is true only if you prepay six months; one month costs $199.99. Enclomiphene's $99.99 needs a full year. Hair products quote a monthly number but ship in 90-day blocks. None of this is hidden — the plan tiers are right there on the page — but the advertised figure is always the one requiring the largest commitment, and no cancellation terms are published for those plans. That combination puts real money at risk on a service you have not tried.
• •The complaint record describes a fulfilment problem rather than a clinical one. Across seven BBB complaints the recurring shape is the same: the subscription bills reliably, the treatment does not arrive reliably. One customer put it as billing 'immediately and regardless of whether they have provided any treatment'. Another described being charged after service had stopped entirely. Maximus refunded both, at $419.97 and $749.97, and refunded a third at $1,392.63 after a twenty-day service lapse. Seven complaints against a company of this size is not a scandal, and answering all of them is more than most manage. But they cluster, and they cluster on the thing you are paying for.
• •The enclomiphene position deserves your attention if fertility is why you are here. FDA's Pharmacy Compounding Advisory Committee voted 8–4 against putting enclomiphene citrate on the 503A Bulks List in June 2022, one member citing lack of convincing efficacy evidence. The vote is advisory, the rule is not final, and compounding continues lawfully under interim policy — but 'protects your fertility' is being marketed on a molecule that has never cleared FDA approval and that FDA's own advisers recommended against. Raise it with the prescriber.
• •Set against all that, the disclosure genuinely is best-in-class. Maximus publishes transference risk, spermatogenesis suppression, polycythaemia, PSA elevation, sleep apnoea and cardiovascular risk on a page selling testosterone cream. It publishes vardenafil's QT effect and the nitrate contraindication on a page selling ED medication. It volunteers the base-form compounding question. Across this review series, providers that disclose this thoroughly are rare, and it is not a small thing — it is the difference between informed consent and a checkout flow.
• •One small credibility note: the sermorelin page advertises the same $199.99 product as both 'less than $6/day' and 'under $9/day'. At $199.99 a month it is about $6.58. Minor, but on a site this careful about pharmacology it is a reminder to check the arithmetic on every claim yourself.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Maximus is the best-disclosing company in men's telehealth and one of the more frustrating ones to buy from. On a page selling testosterone cream it tells you the drug can transfer to your children, suppress your fertility, thicken your blood, raise your PSA and worsen sleep apnoea. On a page selling ED medication it tells you vardenafil prolongs the QT interval. It volunteers that it compounds base-form rather than salt-form semaglutide, a question its competitors will not answer. That is not marketing; that is a company treating informed consent as part of the product.

The catalogue backs it up. Four testosterone protocols, compounded and brand-name GLP-1s, PDE5 inhibitors from $35.99, hair medication from $24.99, sermorelin, oxytocin and 146-marker lab panels — no one else in this series covers that much ground, and the entry prices are genuinely competitive.

Then the commercial layer undercuts it. Every advertised price is the long-plan rate: $99.99 testosterone means prepaying six months, and one month is $199.99. Enclomiphene's $99.99 needs a year. And Maximus publishes no cancellation terms for any of those prepaid plans — the one disclosure that would cost it money is the one missing. Meanwhile its seven BBB complaints cluster on a single theme: the billing works, the fulfilment sometimes does not. Twenty-day service lapses, prescriptions to the wrong pharmacy, six-week provider waits, charges continuing after service stopped. Maximus answered all seven and refunded four figures more than once, which is why it holds a B+ and why we still rate it well — but those refunds trace a real operational weakness.

One more thing to weigh if fertility is your reason for being here. The enclomiphene protocols are the ones Maximus promotes hardest, and enclomiphene has no FDA-approved product; FDA's own Pharmacy Compounding Advisory Committee voted 8–4 against listing it for compounding in June 2022. Lawful, widely prescribed, and not the settled science the landing page implies. Ask about it.

We rate Maximus 4.0 out of 5 — exceptional transparency about medicine, insufficient transparency about money, and a fulfilment record that has cost several customers real time and cash before the refund arrived.

Buy it if you want several protocols under one clinician and will commit six months deliberately rather than because a headline price nudged you there. Before you pay, get three things in writing: your total on the plan length you are choosing, what happens if you cancel early, and what lab monitoring is included. If you only want GLP-1 weight loss, a no-commitment provider is simpler and cheaper.

This review is informational only and is not medical advice. Compounded medications, including compounded testosterone, enclomiphene, sermorelin and compounded GLP-1s, are not FDA-approved. Speak to a licensed clinician about whether any of this is appropriate for you before starting, changing or stopping treatment.